Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2009

Open Access 01-12-2009 | Melanomas

S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients

Authors: S. Kruijff, MD, E. Bastiaannet, MSc, A. C. Muller Kobold, MSc, PhD, R. J. van Ginkel, MD, PhD, A. J. H. Suurmeijer, MD, PhD, H. J. Hoekstra, MD, PhD

Published in: Annals of Surgical Oncology | Issue 12/2009

Login to get access

Abstract

Background

Elevation of the tumor marker S-100B in melanoma patients is a highly specific indicator of recurrence.

Materials and methods

The role of S-100B in disease-free survival (DFS) was evaluated in stage III melanoma patients (staged with fluorodeoxyglucose positron emission tomography [FDG-PET] and computed tomography [CT]) with palpable lymph node metastases who underwent therapeutic lymph node dissection. S-100B and LDH were measured on the day before surgery (d = −1) and on days 1, 2, and 7 postoperatively. Multivariate logistic regression was used to study factors associated with preoperative elevation of S-100B. Univariate (log-rank test) and multivariate (Cox regression) survival analyses were performed to identify factors associated with DFS.

Results

Between 2004 and 2008, 56 patients (median age 57, range 24–93) years, 27 males (48%) and 29 females (52%) entered the study. Preoperative S-100B elevation was found in 27 patients (48%) and elevated LDH in 20 patients (36%). No association was found between these two markers at any time. Multivariate analysis showed that elevated S-100B preoperatively (hazard ratio [HR] 2.7, P = .03) was associated with DFS. S-100B elevation was associated with increased tumor size (odds ratio [OR] 3.40; P = .03).

Conclusion

Elevated S-100B preoperatively in patients with optimally staged clinical stage III melanoma is associated with decreased disease-free survival. S100-B could be used as a prognostic marker in the stratification of new adjuvant trials to select stage III melanoma patients for adjuvant systematic treatment.
Literature
1.
Siesling S, Visser O, van Dijck JA, Coebergh JW. Trends in the incidence and death from cancer from 1989-2003 in The Netherlands. Ned Tijdschr Geneeskd. 2006;150:2490–6.PubMed
2.
Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17:117–27.CrossRefPubMed
3.
Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6:608–21.CrossRefPubMed
4.
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.CrossRefPubMed
5.
Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients. Validation of the American Joint Committee on Cancer melanoma system. J Clin Oncol. 2001;19:3622–34.PubMed
6.
Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS, Wobbes T, Jager PL, et al. Impact of 18F fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg. 2006;93:243–9.CrossRefPubMed
7.
Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, et al. Prospective comparison of FDG-PET and CT in 251 melanoma patients with palpable lymph node metastases; diagnostic accuracy and impact on treatment. J Clin Oncol. (in press).
8.
Bastiaannet E, Hoekstra OS, Oyen WJ, Jager PL, Wobbes T, Hoekstra HJ. Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases. Ann Surg Oncol. 2006;13:919–26.CrossRefPubMed
9.
10.
11.
Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol. 1996;3:446–52.CrossRefPubMed
12.
Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993;72:3091–8.CrossRefPubMed
13.
Fagnart OC, Sindic CJ, Laterre C. Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem. 1988;34:1387–91.PubMed
14.
Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995;31A:924–8.CrossRefPubMed
15.
Smit LH, Korse CM, Hart AA, Bonfrer JM, Haanen JB, Kerst JM, et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer. 2005;41:386–92.CrossRefPubMed
16.
Jackel A, Deichmann M, Waldmann V, Bock M, Näher H. S-100 beta protein in serum, a tumor marker in malignant melanoma—current state of knowledge and clinical experience. Hautarzt. 1999;50:250–6.CrossRefPubMed
17.
Bastiaannet E, Beukema JC, Hoekstra HJ. Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev. 2005;31:18–26.CrossRefPubMed
18.
Henderson MA, Burmeister B, Thompson JF, Di Iulio J,Fisher R, Hong A, et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial. 2009 ASCO Annual meeting, J Clin Oncol. 2009;27 Supplement: Abstract No. LBA9084.
19.
Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, et al. On the release and half life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer. 2001;94:586–90.CrossRefPubMed
20.
Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Månsson Brahme E, Ringborg U, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 2001;19:824–31.PubMed
21.
Mohammed MQ, Abraha HD, Sherwood RA, MacRae K, Retsas S. Serum S100beta protein as a marker of disease activity in patients with malignant melanoma. Med Oncol. 2001;18:109–20.CrossRefPubMed
22.
Curry BJ, Farrelly M, Hersey P. Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I–III melanoma. Melanoma Res. 1999;9:557–67.PubMedCrossRef
23.
Bonfrer JM, Korse CM, Nieweg OE, Rankin EM. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer. 1998;77:2210–4.PubMed
24.
Buer J, Probst M, Franzke A, Duensing S, Haindl J, Volkenandt M, et al. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer. 1997;75:1373–6.PubMed
25.
Hansson LO, von SE, Djureen E, Hansson J, Nilsson B, Ringborg U. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma. Anticancer Res. 1997;17:3071–3.PubMed
26.
Bonfrer JM, Korse CM, Israels SP. Serum S-100 has prognostic significance in malignant melanoma. Anticancer Res. 1997;17:2975–7.PubMed
27.
Hamberg AP, Korse CM, Bonfrer JM, de Gast GC. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 2003;13:45–9.CrossRefPubMed
28.
Hauschild A, Engel G, Brenner W, Gläser R, Mönig H, Henze E, et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol. 1999;140:1065–71.CrossRefPubMed
29.
Henze G, Dummer R, Joller-Jemelka HI, Böni R, Burg G. Serum S100—a marker for disease monitoring in metastatic melanoma. Dermatology. 1997;194:208–12.CrossRefPubMed
30.
Banfalvi T, Boldizsar M, Gergye M, Gilde K, Kremmer T, Otto S. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III–IV malignant melanoma. Pathol Oncol Res. 2002;8:183–7.CrossRefPubMed
31.
Banfalvi T, Gilde K, Gergye M, Boldizsar M, Kremmer T, Otto S. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma. Eur J Cancer. 2003;39:164–9.CrossRefPubMed
32.
Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer. 2003;97:1737–45.CrossRefPubMed
33.
Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, et al. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol. 2007;28:264–72.CrossRefPubMed
34.
Smit LH, Nieweg OE, Korse CM, Bonfrer JM, Kroon BB. Significance of serum S-100B in melanoma patients before and after sentinel node biopsy. J Surg Oncol. 2005;90:66–9.CrossRefPubMed
35.
Chun YS, Wang Y, Wang, DY, McClain DM, Lucci A, Mansfield PF, et al. S100B levels are more accurate than LDH levels at predicting survival in melanoma patients. Ann Surg Oncol. 2008;15:96 (P211).CrossRef
36.
Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: A meta-analysis. Int J Cancer. 2008;123:2370–6.CrossRefPubMed
37.
Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B surgically resected melanoma Patients Participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009;27:38–44.CrossRefPubMed
38.
Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini PA, Rapaport D, et al. Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol. 1996;3:558–63.CrossRefPubMed
39.
Abraha HD, Fuller LC, Du Vivier AW, Higgins EM, Sherwood RA. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol. 1997;137:381–5.CrossRefPubMed
40.
Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 1997;57:3149–53.PubMed
41.
Tofani A, Cioffi RP, Sciuto R, Rea S, Festa A, Di Filippo F, et al. S-100 and NSE as serum markers in melanoma. Acta Oncol. 1997;36:761–4.CrossRefPubMed
42.
Schultz ES, Diepgen TL, Von Den DP. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol. 1998;138:426–30.CrossRefPubMed
43.
Bonfrer JM, Korse CM. Monitoring malignant melanoma with the S-100B tumour marker. Recent Results Cancer Res. 2001;158:149–57.PubMed
44.
Seregni E, Massaron S, Martinetti A, Illeni MT, Rovini D, Belli F, et al. S100 protein serum levels in cutaneous malignant melanoma. Oncol Rep. 1998;5:601–4.PubMed
45.
Hauschild A, Engel G, Brenner W, Gläser R, Mönig H, Henze E, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology. 1999;56:338–44.CrossRefPubMed
46.
Berking C, Schlupen EM, Schrader A, Atzpodien J, Volkenandt M. Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmunometric assay for S-100. Arch Dermatol Res. 1999;291:479–84.CrossRefPubMed
47.
Kaskel P, Berking C, Sander S, Volkenandt M, Peter RU, Krähn G. S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma. J Am Acad Dermatol. 1999;41:962–9.CrossRefPubMed
48.
Brouard M, Quillien V, Ollivier I, Lesimple T, Adamski H, Chevrant-Breton J. Serum S100B protein and stage of cutaneous melanoma: a prospective study. Ann Dermatol Venereol. 2000;127:56–9.PubMed
49.
Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, Parvinen LM, Hahka-Kemppinen M, Korpela M, et al. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma. Melanoma Res. 2000;10:237–41.PubMed
50.
Jury CS, McAllister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol. 2000;143:269–74.CrossRefPubMed
51.
Juergensen A, Holzapfel U, Hein R, Stolz W, Buettner R, Bosserhoff A. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Tumour Biol. 2001;22:54–8.CrossRefPubMed
52.
Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H. Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer. 2002;100:580–5.CrossRefPubMed
53.
Andres R, Mayordomo JI, Zaballos P, Rodino J, Isla D, Escudero P, et al. Prognostic value of serum S-100B in malignant melanoma. Tumori. 2004;90:607–10.PubMed
54.
55.
Schmidt H, Sorensen BS, Fode K, Nexo E, von der Maase H. Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res. 2005;15:409–16.CrossRefPubMed
56.
Cao MG, Auge JM, Molina R, Marti R, Carrera C, Castel T, et al. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res. 2007;27:595–9.PubMed
Metadata
Title
S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients
Authors
S. Kruijff, MD
E. Bastiaannet, MSc
A. C. Muller Kobold, MSc, PhD
R. J. van Ginkel, MD, PhD
A. J. H. Suurmeijer, MD, PhD
H. J. Hoekstra, MD, PhD
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0629-8

Other articles of this Issue 12/2009

Annals of Surgical Oncology 12/2009 Go to the issue

Colorectal Cancer

Intramucosal Carcinoma on Biopsy Reliably Predicts Invasive Colorectal Cancer

Healthcare Policy and Outcomes

Outcome of Low-Volume Surgery for Esophageal Cancer in a High-Volume Referral Center

Endocrine Tumors

Utility of Intraoperative PTH for Primary Hyperparathyroidism Due to Multigland Disease

Breast Oncology

Prognostic Factors in 77 Curative Chest Wall Resections for Isolated Breast Cancer Recurrence

Bone and Soft Tissue Sarcomas

Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1 mg and Melphalan (T1-M HILP) Is Safe and Efficient

Colorectal Cancer

Notch2 Expression Is Decreased in Colorectal Cancer and Related to Tumor Differentiation Status